The preliminary efficacy and safety results of neoadjuvant phase II study of anlotinib plus tislelizumab combined with chemotherapy in triple-negative breast cancer. This is an ASCO Meeting Abstract ...
Morning Overview on MSN
Ozempic-style drugs were linked to about 30% lower breast-cancer odds in a 111,000-woman study
Researchers at the University of Pennsylvania analyzed data from 111,646 women and found that those who used GLP-1 receptor agonists, the drug class that includes semaglutide (sold as Ozempic and ...
Utility of breast MRI for patients with breast-cancer scheduled for breast-conserving surgery. Background: Patients with biopsy-proven Stage I and Stage II breast cancer usually undergo pre-operative ...
Findings from a study published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results